Tarix begins patient enrollment for TXA127 Phase 1 study in DCBT

March 26, 2017

INNO-206 is designed to control the release of the commonly prescribed chemotherapeutic doxorubicin and to preferentially target tumors, which the Company believes may make it more effective and less toxic in cancer patients than doxorubicin. Objective clinical responses have been reported in patients with sarcoma, breast and small cell lung cancers. CytRx is currently conducting a Phase 1b safety and dose escalation study with INNO-206 in patients with advanced solid tumors who have failed standard therapies and in the second half of this year, anticipates moving into Phase 2 clinical testing for patients suffering from soft tissue sarcoma.

In July 2009, CytRx announced positive results from an animal trial with a human model of pancreatic cancer. In this trial, treatment with INNO-206 resulted in a statistically significant (p<0.005) three-fold reduction in the average primary tumor size, compared to the control. Treatment with doxorubicin showed only a 30% primary tumor reduction, which was not statistically significant. In a parallel experiment, treatment with gemcitabine, the approved and most commonly prescribed drug for pancreatic cancer, resulted in activity comparable to doxorubicin, with an approximate 30% primary tumor volume reduction. Additionally, although no statistically significant inhibition of tumor spread was demonstrated by either INNO-206 or gemcitabine, due to large variability between individual animals in the control, a substantial trend was observed in the INNO-206 group with an approximate 10-fold decrease in tumor spread to the liver and stomach. The toxicity associated with drug treatment was comparable among the treated groups.

SOURCE CytRx Corporation